

# Protégé

Paclitaxel Coated Coronary Balloon Dilatation Catheter



### Taking **DCB Technology to a New High**

÷

44



A Translumina Group Company

## Protégé

Paclitaxel Coated Coronary Balloon Dilatation Catheter

### PACLITAXEL

Drug of Choice for DCB in Coronary Interventions with Large Clinical Evidence<sup>1</sup>



3. Clin Res Cardiol (2015) 104:217-225 4. Circ Res. 2000;86:879-884

### **UNIQUE DRUG APPLICATION**

Drug is applied through auto pipette technology with in the balloon folds ensuring minimum drug loss





Paclitaxel applied to balloon surface Over PVP Coating

Wrapped Balloon

### WING SEAL TECHNOLOGY

Wrapped balloon is crimped & then subjected to a process that creates corrugation



- Crimping prevents balloon unfolding during advancement and minimizes drug loss
- Surface corrugation creates low balloon profile for better flexibility & deliverability even in complex anatomy
- Corrugation reduces frictional abrasion during balloon advancement



### M3i STUDY



\*Data on File

World's First and Only Ion-Complian DCB

\* \*

### Protégé NC

Paclitaxel Coated Coronary Balloon Dilatation Catheter

Linear Expansion with no over growth at high pressure

NC balloons minimize dissection in complex lesion subset compared to SC balloons\*

> For the treatment of ISR and lesions difficult to dilate

Higher strength than Semi-Compliant DCB\*\*

\*Desmet, W. J., De Scheerder, I. K., Barrios, L., & Piessens, J. H. (1997). Catheter Cardiovasc Diagn, 41(1), 5–11. \*\*Amstutz, C., Behr, J., Krebs, S., Haeberlin, A., Vogel, R., Zurbuchen, A., & Burge, J. (2023). BioMedical Engineering OnLine, 22(94)

### Paclitaxel Coated Coronary Balloon Dilatation Catheter

### Proven safety and efficacy of the Protégé\*

In real-world PCI of In-Stent Restenosis (ISR) and De Novo Lesions





### **Conclusions: at 2 Years Follow-Up**

Protege Paclitaxel DCB is proven safe and effective in patients treated for ISR and De Novo Lesions



At 2 years MACE rates after DCB for De Novo Lesions was **9.7%** showing better efficacy and safety At 2 years MACE driven by TLR in patients treated for ISR was **(11.7%)** & for De Novo Lesions **(2.9%)** which is lower compared to the reported incidence rates in ISR patients (>15%)



#### PROTÉGÉ - DCB CATHETER

LØ	2.00	2.50	3.00	3.50	4.00
10	PRO2010	PRO2510	PRO3010	PRO3510	PRO4010
15	PRO2015	PRO2515	PRO3015	PRO3515	PRO4015
20	PRO2020	PRO2520	PRO3020	PRO3520	PRO4020
30	PRO2030	PRO2530	PRO3030	PRO3530	PRO4030

#### PROTÉGÉ NC - DCB CATHETER

LØ	2.50	2.75	3.00	3.25	3.50	4.00	4.50
10	PNC2510	PNC2710	PNC3010	PNC3210	PNC3510	PNC4010	PNC4510
15	PNC2515	PNC2715	PNC3015	PNC3215	PNC3515	PNC4015	PNC4515
20	PNC2520	PNC2720	PNC3020	PNC3220	PNC3520	PNC4020	PNC4520

(Ø = Diameter, L = Length)



### **TECHNICAL** SPECIFICATIONS

|--|

Nominal Pressure	6 bar	12 bar
Rated Burst Pressure	16 bar (Ø 4,0= 13 bar)	Ø 2.00 - 2.75: 22 bar Ø 3.00 - 3.50: 20 bar Ø 4.00 - 4.50: 18 bar
Folding	3-folds WingSeal	3-folds WingSeal
Drug	Paclitaxel 3 µg/mm²(drug loaded balloon surface)	Paclitaxel 3 µg/mm²(drug loaded balloon surface)
Guiding catheter compatibility	5F	5F
Guide wire compatibility	0.014" (0.36mm)	0.014" (0.36mm)
Catheter type	Rapid Exchange	Rapid Exchange
Usable length	154 cm	154 cm
Catheter Coating	Hydrophilic coating	Hydrophilic coating

C € 2797

BLUE MEDICAL DEVICES B.V. A Translumina Group Company Panovenweg 7 5708 HR Helmond The Netherlands Phone: +31 (0) 492588900 Email: info@translumina.de Indications, contraindications, warnings and instruction for use can be found in the product labeling

▲ Caution- Restricted to sale by or on the order of a physician

#### translumina

PROTÉGÉ NC - DCB CATHETER

LIMITLESS POSSIBILITIES



www.translumina.com

PRO9.0010.02 10/2024